Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Liabilities for 15 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • Quarterly Total Liabilities fell 44.82% to $1.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2025, down 44.82% year-over-year, with the annual reading at $2.4 million for FY2025, 6.35% down from the prior year.
  • Total Liabilities for Q3 2025 was $1.7 million at IGC Pharma, down from $1.9 million in the prior quarter.
  • The five-year high for Total Liabilities was $3.1 million in Q1 2021, with the low at $1.7 million in Q3 2025.
  • Average Total Liabilities over 5 years is $2.4 million, with a median of $2.4 million recorded in 2025.
  • The sharpest move saw Total Liabilities soared 32.75% in 2023, then crashed 44.82% in 2025.
  • Over 5 years, Total Liabilities stood at $1.8 million in 2021, then dropped by 3.31% to $1.8 million in 2022, then rose by 25.84% to $2.2 million in 2023, then increased by 27.79% to $2.8 million in 2024, then crashed by 41.43% to $1.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $1.7 million, $1.9 million, and $2.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.